Novo Nordisk

Novo Nordisk A/S Monitor

Novo Nordisk A/S Annual Report Year
CR Monitor Issue: 
2018/0307
Company covered: 
Novo Nordisk A/S
Period End: 
31 December, 2017
Report issued on 13 March 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of new accounting standards issued but not yet effective including IFRS 9, IFRS 15 and IFRS 16.
Change
Structure of geographic segment information altered.
Change
Additional disclosure in respect of research and development milestone payments
New
Disclosure of social accounting policies extended.

Other Comprehensive Income: Presentation of items by reclassification status an emerging issue under IFRS

This report considers the presentation of other comprehensive income following the issue of amendments to IAS 1 “Presentation of financial statements”. It considers how the various line items that represent other comprehensive income are reported by nature focusing on the presentational split between those items that will not be reclassified subsequently to profit or loss and those that will be reclassified to profit or loss when specific conditions are met. 

IAS 19 Revised "Employee Benefits", an emerging issue under IFRS

This report focuses on the early adoption of amendments to IAS 19 “Employee benefits”. It considers three main areas: the recognition of actuarial gains and losses in other comprehensive income rather than partial recognition through profit or loss; the replacement of interest cost and expected return on plan assets with a net interest amount that is calculated by applying a discount rate to the net defined benefit obligation / asset; and the recognition of past service costs.

Gains And Losses Linked To Associated Undertakings, an emerging issue under IFRS

This report examines where in the income statement gains and losses linked to an associate, that are separate from the share of profit or loss of the associate, are presented.

Novo Nordisk A/S Period End 31 December 2010

Novo Nordisk A/S Annual Report 2010
Gain on disposal included in share of profit of associates income statement line item
Danish healthcare company Novo Nordisk includes a DKK1.06 billion gain on disposal of an associate in its income statement line share of profit of associated companies.

Novo Nordisk A/S Period End 31 December 2009

Aggregation criteria applied to disclosure of other comprehensive income and tax effects
Danish healthcare company Novo Nordisk applies aggregation to the components and tax effects of other comprehensive income that, on the face of it, conflicts with IFRS but tells us that this is on the grounds of materiality.